Logo-bi
Original Research
Adel Rezaei-Moghadam, Daryoush Mohajeri, Behnam Rafiei, Rana Dizaji, Asghar Azhdari, Mahdi Yeganehzad, Maryamossadat Shahidi, Mohammad Mazani*
Bioimpacts. 2012;2(3): 151-157. doi: 10.5681/bi.2012.020
PMCID: PMC3648928     PMID: 23678453     Scopus ID: 84876731451    
PDF
XML
Cited By:
Original Research
Samaneh Rashtbari, Gholamreza Dehghan*, Reza Yekta, Abolghasem Jouyban
Bioimpacts. 2017;7(3): 147-153. doi: 10.15171/bi.2017.18
PMCID: PMC5684506     PMID: 29159142     Scopus ID: 85032025147    
Original Article
Mina Yousefnezhad, Soodabeh Davaran* ORCID, Mirzaagha Babazadeh, Abolfazl Akbarzadeh, Hamidreza Pazoki-Toroudi
Bioimpacts. 2023;13(3): 241-253. doi: 10.34172/bi.2023.24252
PMCID: PMC10329752     PMID: 37431480     Scopus ID: 85157052599    
Drug repurposing is an effective strategy for identifying and using approved drugs for new therapeutic purposes. We investigated co-delivery of the antitumor drugs, doxorubicin (DOX), and ezetimibe (EZ) as a cholesterol uptake-blocking drug with PCEC on prostate cancer cell line (PC3).
Original Article
Zahra Bahadoran ORCID, Parvin Mirmiran, Fereidoun Azizi, Asghar Ghasemi* ORCID
Bioimpacts. 2024;14(5): 29917. doi: 10.34172/bi.2024.29917
PMCID: PMC11406430     PMID: 39296799     Scopus ID: 85209255799    
Review
Nilesh Tipan* ORCID, Ajay Pandey, Pushyamitra Mishra
Bioimpacts. 2025;15: 30010 | Published on: 2024 Jun 29. doi: 10.34172/bi.30010
PDF
XML
Cited By:
Review
Sepideh Sohrabi ORCID, Shiva Alipour ORCID, Zahra Ghahramanipour ORCID, Javad Masoumi, Behzad Baradaran* ORCID
Bioimpacts. 2025;15: 30030 | Published on: 2024 May 11. doi: 10.34172/bi.30030
PDF
XML
Cited By:
Original Article Special issue | AI & Bioinformatics
Gelareh Vahabzadeh ORCID, Amirreza Pashapour-Yeganeh, Maryam Eini, Morad Roudbaraki, Ebrahim Esmati, Amirhoushang Poorkhani, Solmaz Khalighfard, Ali Mohammad Alizadeh* ORCID
Bioimpacts. 2025;15: 30510 | Published on: 2025 Jan 26. doi: 10.34172/bi.30510


As a peer-reviewed international open-access journal, BioImpacts publishes articles on basic and translational aspects of pharmaceutical and biomedical sciences. 
Acceptance rate: 24% 
Publication fee: Free of charge